Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Authors
Javle, MBorbath, I
Clarke, S
Hitre, E
Louver, C
Macarulla, T
Oh, D
Spratlin, J
Valle, Juan W
Weiss, K
Berman, C
Howland, M
Ye, Y
Cho, T
Moran, S
Abou-Alfa, C
Affiliation
MD Anderson Cancer Center, Houston, TexasIssue Date
2019
Metadata
Show full item recordCitation
Javle M, Borbath I, Clarke S, Hitre E, Louvet C, Macarulla T, et al. P-225 Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. Ann Oncol. 2019;30(Supplement_4):62.Journal
Annals of OncologyDOI
10.1093/annonc/mdz155.224Additional Links
https://dx.doi.org/10.1093/annonc/mdz155.224Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz155.224